New Insights into the Management of Metastatic Bladder Cancer: Expert Strategies and Treatment Considerations for Managed Care

 A continuing medical education and nursing continuing professional
development activity provided by NAMCP and AAMCN.

This activity is an archive from the live session from the 2023 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2024 to March 1, 2025
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Merck Sharp & Dohme LLC and Seagen

Description:
Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. According to the American Cancer Society, there were an estimated 82,290 new cases of bladder cancer and 17,100 deaths in the United States in 2022. Before the advent of new treatments in recent years, the basic management of this illness has remained unchanged for decades. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. As the role of the immune system in oncogenesis and therapy has become clearer across cancer types, new approaches emerged with important benefits in metastatic bladder cancer, which led to the introduction of immune checkpoint inhibitors. However, when those options fail, and when patients are ineligible for cisplatin-containing chemotherapy, options are sparse to manage this difficult disease. Fortunately for patients with metastatic bladder cancer, new agents, including antibody-drug conjugates both alone and in combination with immunotherapies, have recently emerged for patients with metastatic bladder cancer, especially in patients who are ineligible for cisplatin-containing chemotherapy. It is for this reason that medical directors, oncologists, practicing physicians, nurse case managers and other healthcare professionals must be educated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the metastatic bladder cancer patient population.

Upon completion of this activity, participants will be able to:

  • Explore the clinical and economic burden of locally advanced/metastatic urothelial cancer (mUC), including factors that contribute to poor prognosis and increased costs

  • Compare the current standard treatment options for locally advanced/mUC including their benefits, limitations, and recommendations for use

  • Analyze the mechanisms, efficacy, and safety data for current and emerging agents and combination regimens to inform treatment selection and sequencing strategies

  • Examine the evolving role and impact of anti-PD-1 therapy in the management of metastatic bladder cancer

  • Assess the current role and impact of antibody-drug conjugates, both alone and in combination with immunotherapies, in the management of locally advanced/mUC

  • Examine the managed care considerations of current and emerging therapies, including antibody-drug conjugates and checkpoint inhibitors, to help improve the clinical and economic burden of patients with locally advanced/mUC
     

Faculty:
Jones Nauseef, MD, PhD
Assistant Professor of Medicine
Division of Hematology & Medical Oncology
Sandra and Edward Meyer Cancer Center
Weill Cornell Medicine

Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.

Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Nauseef has served as a consultant for AIQ, Bayer, and Pfizer. He has served on an advisory board for Bayer and Pfizer. All relevant conflicts of interest have been mitigated.

Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.

This activity is supported by educational grants from
Merck Sharp & Dohme LLC and Seagen


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue